Výsledky vyhledávání

Kniha

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Results of a survey of the role of multidisciplinary team coordinators for colorectal cancer in England and Wales

Autor: C. L. Ingham-Clark, M. J. Kelly, D. Soukop, A. Robinson, M. Soukop

Publikováno v: Colorectal Disease. 9:146-150

Objective Over the last 6 years, multidisciplinary teams (MDTs) have been established and play a key role in organizing the delivery of cancer care in the UK. There are no published data on the roles of their co-coordinators. To seek the views of col

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd1ebfdbc99e620fe73e39b077ebb6e3
https://doi.org/10.1111/j.1463-1318.2006.01027.x

Zobrazit plný text záznamu

A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

Publikováno v: Cancer Chemotherapy and Pharmacology. 53:341-348

Idoxifene is a novel selective oestrogen receptor modulator (SERM) which had greater binding affinity for the oestrogen receptor (ER) and reduced agonist activity compared with tamoxifen in preclinical studies. In a randomized phase II trial in 56 po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::732c071ca26af2308c155a94950de380
https://doi.org/10.1007/s00280-003-0733-6

Zobrazit plný text záznamu

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma

Autor: R. Blackie, N. Raby, Grant Fullarton, A. C. McDonald, G. Pentheroudakis, R. Morrison, M. Soukop, T. R. J. Evans, A. McInnes, James Paul

Publikováno v: Annals of Oncology. 13:1469-1478

Background: The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma. Res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28a961153c525c643ef9c08f5dc374b9
https://doi.org/10.1093/annonc/mdf243

Zobrazit plný text záznamu

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

Autor: Malcolm R Ranson, Alan T McGown, Barry W. Hancock, A Robbins, Gordon C Jayson, Gavin Halbert, Fiona H Blackhall, John Radford, M. Soukop

Publikováno v: British Journal of Cancer

Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive non-Hodgkin's lymphoma of indol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff3c517eaf44d7689153258c47e681f
https://doi.org/10.1054/bjoc.2000.1624

Zobrazit plný text záznamu

True

Autor: Thomas R. Jeffry Evans, D A Anthony, P. Wilson, Martin Eatock, M El-Abassi, James Paul, M. Soukop, M Smith

Publikováno v: British Journal of Cancer. 82:1925-1931

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fc7fe49fe1220db0f3dc3586e7f5080
https://doi.org/10.1054/bjoc.2000.1165

Zobrazit plný text záznamu

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease

Autor: N. S. Reed, D. Dunlop, M. Soukop, W. Steward, M. M. Eatock, Eric J Fitzsimmons, S. Anderson, N. P. Lucie, P. Tansey, James Paul

Publikováno v: Clinical Oncology. 10:107-114

This study was intended to ascertain whether the adjunctive administration of filgrastim (r metHuG-CSF, Amgen) would influence the dose intensity of chemotherapy or the morbidity of myelosuppression in patients receiving MOPP or MOPP/EVAP hybrid chem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aae69e5fa50c4d8d7f9f1141a1968014
https://doi.org/10.1016/s0936-6555(05)80490-x

Zobrazit plný text záznamu

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

Autor: Allan B. MacLean, CR Lewis, Stan B. Kaye, Derek Cruickshank, S. M. Crawford, J. Kennedy, David E. Parkin, James Paul, Henry C Kitchener, T. K. Sarkar, N. S. Reed, H.K. Gordon, M. Soukop, R. Atkinson, R P Symonds, Jim Cassidy, I. D. Duncan, E M Rankin, J. Davis

Publikováno v: Journal of Clinical Oncology. 14:2113-2119

PURPOSE In 1992, we reported the first results of a randomized study in ovarian cancer, comprising two doses of cisplatin and indicated a significant difference (P = .0008) in median survival. Four years later, we now describe the results of this tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1628d763798a1d1ca31a365626ede196
https://doi.org/10.1200/jco.1996.14.7.2113

Zobrazit plný text záznamu

Prognostic factor analysis, for patients with no evidence of disease after initial chemotherapy for advanced epithelial ovarian carcinoma

Autor: J. Kennedy, R. Atkinson, J.A. Davis, Stan B. Kaye, M. Soukop, A.B. MacLean, R.I. Lopez, Jim Cassidy, James Paul, HC Kitchener, W. Fullerton, E. Pyper, I. D. Duncan

Publikováno v: International Journal of Gynecological Cancer. 6:8-14

Although the results from chemotherapy for advanced ovarian carcinoma have improved over the past 15 years with the introduction of platinum compounds, there are still a large number of patients who will relapse from complete response (clinical or pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19ad988dd2e9e08715773fdc92ec2202
https://doi.org/10.1046/j.1525-1438.1996.06010008.x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání